In Vitro Screening CROs in United States

Global leader in providing preclinical and clinical laboratory services. Charles River offers early-stage discovery, safety assessment, and clinical support services to pharmaceutical and biotech companies worldwide.

Preclinical ADME and pharmacokinetics CRO in Pennsylvania providing in vitro and in vivo absorption, distribution, metabolism, and excretion studies as part of Pharmaron's global network.

Preclinical ADME and pharmacokinetic service provider now part of Pharmaron. Specializes in in vitro and in vivo DMPK, drug transporter studies, and metabolite identification.

San Diego-based preclinical CRO providing in vitro ADME screening, permeability assays, and metabolic stability studies for drug discovery programmes.

GLP-compliant preclinical CRO in Austin, Texas, offering 100+ validated xenograft efficacy models, IND-enabling toxicology, and RNAi therapeutic development services.

Specialty preclinical CRO offering bioanalytical chemistry, in vitro ADME screening, physicochemical profiling, and metabolite identification for drug discovery programs.

Global CRO/CDMO providing integrated drug discovery and development services including medicinal chemistry, ADME/PK, pharmacology, and process chemistry from US and China operations.

Preclinical CRO specialising in immunotoxicology and immune safety assessment, offering in vivo and in vitro studies for pharma, biotech, and government clients.

AI-enabled precision oncology CRO using patient-derived xenograft models and ex vivo pharmacology to generate predictive therapeutic response data for drug developers.

Precision oncology CRO using patient-derived orthotopic xenograft models and predictive AI to guide drug selection and oncology development decisions.

Specialty CRO focused on translational oncology services. Champions provides patient-derived xenograft (PDX) tumor models, ex vivo tumor platforms, and oncology pharmacology studies.

Preclinical oncology CRO using patient-derived tumor models and TumorGraft technology for in vivo efficacy studies, providing translational research services for oncology drug development.

Translational oncology and metabolic disease CRO providing tumor models (PDX, syngeneic, humanized), oncology pharmacology, and biomarker services for drug discovery.

Kentucky-based preclinical CRO specialising in oncology efficacy studies using proprietary humanised rodent models and patient-derived xenografts for immuno-oncology drug development.

North Carolina-based genetic toxicology CRO providing GLP-compliant Ames, micronucleus, chromosomal aberration, and comet assays for regulatory submissions.

Boulder-based biologic discovery CRO integrating antibody discovery, protein engineering, function-first screening, and early developability assessment for complex biotherapeutics.

Full-continuum preclinical CRO providing integrated in vitro and in vivo services including efficacy, toxicity, biodistribution, and product release studies in small and large animals.

Drug discovery services company providing in vitro pharmacology screening, ADME profiling, and custom assay development for pharmaceutical and biotech companies.

Hanover, Maryland-based drug screening CRO offering high-throughput receptor binding, enzyme inhibition, and functional cell-based assays for hit-to-lead optimisation programmes.

Specialty preclinical CRO focused on non-GLP ophthalmic and oncology efficacy studies, providing in vivo animal model services for ocular disease and solid tumor drug development.

Preclinical CRO specializing in CNS drug discovery using proprietary AI-powered behavioral phenotyping platforms for neurological and psychiatric disorders.

Specialty CRO providing biochemical and cell-based assay services for drug discovery. Known for kinase profiling, epigenetic screening, and custom assay development.

Contract research organization providing discovery, preclinical, and development chemistry services including API synthesis, safety pharmacology, and medicinal chemistry.

Nonprofit research organization providing drug discovery, preclinical development, and analytical services with deep expertise in oncology and infectious disease including BSL-3 capabilities.

New Jersey-based dermatology and personal care CRO conducting clinical trials, product testing, and consumer perception studies for pharmaceutical, cosmetic, and OTC skincare products.

Oncology-focused CRO founded on the Mayo Clinic campus offering preclinical-to-clinical oncology development with PDX models, flow cytometry, and Phase I/II trial management.

New Jersey-based bioanalytical and ADME/DMPK CRO founded in 1987, providing clinical and nonclinical metabolism and pharmacokinetics services to pharma, biotech, and agrochemical industries.

Specialty ADME/PK CRO providing in vitro and in vivo drug metabolism and pharmacokinetic studies. Known for comprehensive ADME characterization using human and animal tissues.

Kansas City-based in vitro ADME and drug metabolism CRO providing hepatocyte-based assays, enzyme induction/inhibition studies, and metabolite identification services.